Literature DB >> 26282091

Is pretreatment cystometry important in predicting response to mirabegron in women with overactive bladder symptoms?

Maya Basu1, Aswini Balachandran2, Jonathan Duckett2.   

Abstract

INTRODUCTION AND HYPOTHESIS: The aim of this study was to evaluate for any association between pretreatment cystometry results and outcome of treatment with mirabegron in women with overactive bladder (OAB) symptoms.
METHODS: This was a prospective observational study of women with OAB symptoms that proved refractory to conservative management. All women underwent filling and voiding subtraction cystometry prior to further treatment. Women were treated with mirabegron 50 mg once daily, and outcomes were evaluated after 6 weeks' treatment. The primary outcome measure was change in symptoms as indicated by response to the Patient Global Impression of Improvement (PGI-I) scale. The presence of detrusor overactivity (DO), the highest detrusor pressure recorded during the filling phase, the presence of urodynamic stress incontinence (USI), cystometric capacity, voided volume, maximum flow rate and detrusor pressure at maximum flow were all compared between responders and nonresponders.
RESULTS: The study population consisted of 169 women; response rate to mirabegron was 69.8 %. There was no association between the presence of DO or maximum detrusor pressure during filling and USI, cystometric capacity, maximum flow rate and detrusor pressure at maximum flow and treatment response. In a subgroup with OAB symptoms refractory to previous treatment with antimuscarinics, there was an association between the presence of DO and a positive treatment response (p = 0.02).
CONCLUSIONS: Overall, there is no association between urodynamic findings and response to treatment with mirabegron. This may reflect the fact that mirabegron's mode of action mechanisms are not measurable using cystometry. In women with refractory symptoms, however, the presence of DO is associated with a positive response to treatment.

Entities:  

Keywords:  Afferent function; Mirabegron; Urodynamics

Mesh:

Substances:

Year:  2015        PMID: 26282091     DOI: 10.1007/s00192-015-2809-3

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  16 in total

1.  Desirable properties of β3-adrenoceptor agonists: implications for the selection of drug development candidates.

Authors:  Martin C Michel; Hana Cernecka; Peter Ochodnicky
Journal:  Eur J Pharmacol       Date:  2011-02-12       Impact factor: 4.432

2.  Pharmacological effect of TRK-380, a novel selective human β3-adrenoceptor agonist, on mammalian detrusor strips.

Authors:  Sayoko Kanie; Atsushi Otsuka; Satoru Yoshikawa; Takashi Morimoto; Nana Hareyama; Seiji Okazaki; Ryosuke Kobayashi; Ko Hasebe; Kaoru Nakao; Ryoji Hayashi; Hidenori Mochizuki; Rikiya Matsumoto; Seiichiro Ozono
Journal:  Urology       Date:  2011-12-23       Impact factor: 2.649

3.  Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.

Authors:  Toshiyuki Takasu; Masashi Ukai; Shuichi Sato; Tetsuo Matsui; Itsuro Nagase; Tatsuya Maruyama; Masao Sasamata; Keiji Miyata; Hisashi Uchida; Osamu Yamaguchi
Journal:  J Pharmacol Exp Ther       Date:  2007-02-09       Impact factor: 4.030

4.  The novel β3-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity.

Authors:  Julie Svalø; Jørgen Nordling; Kirsten Bouchelouche; Karl-Erik Andersson; Cees Korstanje; Pierre Bouchelouche
Journal:  Eur J Pharmacol       Date:  2012-12-12       Impact factor: 4.432

5.  Efficacy of the β3-adrenoceptor agonist mirabegron for the treatment of overactive bladder by severity of incontinence at baseline: a post hoc analysis of pooled data from three randomised phase 3 trials.

Authors:  Christopher Chapple; Vik Khullar; Victor W Nitti; Jeffrey Frankel; Sender Herschorn; Mathilde Kaper; Mary Beth Blauwet; Emad Siddiqui
Journal:  Eur Urol       Date:  2014-08-02       Impact factor: 20.096

6.  Catecholamines relax detrusor through beta 2-adrenoceptors in mouse and beta 3-adrenoceptors in man.

Authors:  Melinda Wuest; Birgit Eichhorn; Marc O Grimm; Manfred P Wirth; Ursula Ravens; Alberto J Kaumann
Journal:  J Pharmacol Exp Ther       Date:  2008-09-26       Impact factor: 4.030

7.  Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study.

Authors:  James G Malone-Lee; Salah Al-Buheissi
Journal:  BJU Int       Date:  2009-03-05       Impact factor: 5.588

8.  Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.

Authors:  Victor W Nitti; Eric S Rovner; Tamara Bavendam
Journal:  BJU Int       Date:  2009-11-04       Impact factor: 5.588

9.  Effects of mirabegron, a novel β3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin.

Authors:  Naoki Aizawa; Yukio Homma; Yasuhiko Igawa
Journal:  Eur Urol       Date:  2012-09-05       Impact factor: 20.096

Review 10.  Antimuscarinics and the overactive detrusor--which is the main mechanism of action?

Authors:  K-E Andersson; M Yoshida
Journal:  Eur Urol       Date:  2003-01       Impact factor: 20.096

View more
  1 in total

1.  False-negative finding in urodynamic study for the chief complaint. Does it interfere with the clinical outcomes for the treatment of SUI or OAB syndromes?

Authors:  Paulo Rodrigues; Flávio Hering; Eli Cielici; Marcio D Império
Journal:  Int Braz J Urol       Date:  2021 May-Jun       Impact factor: 1.541

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.